Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 2/20 | 0.48 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.46 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.46 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.46 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.46 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.46 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1846913 | 0.95 | ALOX5 (0.51) | LTB4RLTB4R2PPARDCYP1A2CYP2C9 | |
| SCHEMBL9221890 | 0.93 | THRA (0.54) | LTB4RLTB4R2PPARDMAPTTHRA | |
| SCHEMBL11349780 | 0.93 | THRA (0.54) | LTB4RLTB4R2PPARDMAPTTHRA | |
| SCHEMBL1536977 | 0.93 | THRA (0.54) | LTB4RLTB4R2PPARDMAPTTHRA | |
| SCHEMBL1017777 | 0.93 | THRA (0.54) | LTB4RLTB4R2PPARDMAPTTHRA | |
| SCHEMBL5472321 | 0.92 | THRA (0.52) | LTB4RLTB4R2PPARDMAPTTHRA | |
| SCHEMBL11856035 | 0.92 | LTB4R (0.50) | LTB4RLTB4R2PPARDCYP1A2CYP2C9 | |
| SCHEMBL5143987 | 0.91 | ALDH1A1 (0.50) | LTB4RLTB4R2PPARDCYP1A2CYP2C9 | |
| SCHEMBL5145487 | 0.91 | ALDH1A1 (0.50) | LTB4RLTB4R2PPARDCYP1A2CYP2C9 | |
| SCHEMBL5143710 | 0.91 | ALDH1A1 (0.50) | LTB4RLTB4R2PPARDCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1526847-A2 | PHARMACEUTICAL DOSAGE FORM COMPRISING A SULFITE COMPOUND | Pharmacia Corporation (US) | 2005-05-04 | — | — | EP | claimed |
| EP-1526845-A2 | PHARMACEUTICAL DOSAGE FORM CAPABLE OF MAINTAINING STABLE DISSOLUTION PROFILE UPON STORAGE | Pharmacia Corporation (US) | 2005-05-04 | — | — | EP | claimed |
| US-20040105883-A1 | Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage | PHARMACIA CORPORATION | 2004-06-03 | — | — | US | claimed |
| US-20040105884-A1 | Pharmaceutical dosage form comprising a sulfite compound | PHARMACIA CORPORATION | 2004-06-03 | — | — | US | claimed |
| WO-2004022032-A2 | PHARMACEUTICAL DOSAGE FORM COMPRISING A SULFITE COMPOUND | PHARMACIA CORPORATION (US) | 2004-03-18 | — | — | WO | claimed |
| WO-2004010973-A2 | PHARMACEUTICAL DOSAGE FORM CAPABLE OF MAINTAINING STABLE DISSOLUTION PROFILE UPON STORAGE | PHARMACIA CORPORATION (US) | 2004-02-05 | — | — | WO | claimed |
| US-6627108-B1 | Salicylic acid, nitrilotriacetic acid, sodium hydroxide, n,n-di-secbutylaminophenol, polyalkylene methylpolysiloxane and water; efficient elemental sulfur recovery | INSTITUT FRANCAIS DU PETROLE (FR) | 2003-09-30 | — | — | US | claimed |
| EP-1274425-A1 | RAPID-ONSET FORMULATION OF A SELECTIVE CYCLOOXIGENASE-2 INHIBITOR | Pharmacia Corporation (US) | 2003-01-15 | — | — | EP | claimed |
| US-20020107250-A1 | Rapid-onset formulation of a selective cyclooxygenase-2 inhibitor | PHARMACIA CORPORATION | 2002-08-08 | — | — | US | claimed |
| WO-2001078724-A1 | RAPID-ONSET FORMULATION OF A SELECTIVE CYCLOOXIGENASE-2 | PHARMACIA CORPORATION (US) | 2001-10-25 | — | — | WO | claimed |
| US-10040751-B2 | Intermediates for macrocyclic compounds | OCERA THERAPEUTICS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180110824-A1 | Macrocyclic Modulators of the Ghrelin Receptor | OCERA THERAPEUTICS, INC. | 2018-04-26 | — | — | US | disclosed |
| US-9949949-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | OCERA THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170042858-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY | 2017-02-16 | — | — | US | disclosed |
| US-9493505-B2 | Macrocyclic modulators of the ghrelin receptor | OCERA THERAPEUTICS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| WO-2002096435-A2 | SKIN-PERMEABLE COMPOSITION COMPRISING A SELECTIVE CYCLOOXYGENASE-2 INHIBITOR A MONOHYDRIC ALCOHOL | PHARMACIA CORPORATION (US) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002083177-A1 | ORALLY DELIVERABLE PHARMACEUTICAL COMPOSITION COMPRISING A DRUG OF LOW WATER SOLUBILITY (COX-2 INHIBITOR), A SOLVENT, A FATTY ACID AND AN ORGANIC AMINE | PHARMACIA CORPORATION (US) | 2002-10-24 | — | — | WO | disclosed |
| US-20020107250-A1 | Rapid-onset formulation of a selective cyclooxygenase-2 inhibitor | PHARMACIA CORPORATION | 2002-08-08 | — | — | US | disclosed |
| WO-2001078724-A1 | RAPID-ONSET FORMULATION OF A SELECTIVE CYCLOOXIGENASE-2 | PHARMACIA CORPORATION (US) | 2001-10-25 | — | — | WO | disclosed |
| EP-0844292-A1 | Composition and use thereof in conversion of a gas containing hydrogen sulfide and sulfur dioxide to sulfur | INSTITUT FRANCAIS DU PETROLE (FR) | 1998-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040751-B2 | Intermediates for macrocyclic compounds | MLNR, CCKAR, CHRM2 | LTB4R 576/4885LTB4R2 528/4885PPARD 1156/4885 |
| US-20180110824-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | LTB4R 1473/4885LTB4R2 1915/4885PPARD 234/4885 |
| US-20040105884-A1 | Pharmaceutical dosage form comprising a sulfite compound | PTGS2, PTGES2, PTGS1 | LTB4R 143/4885LTB4R2 47/4885PPARD 3112/4885 |
| US-20020107250-A1 | Rapid-onset formulation of a selective cyclooxygenase-2 inhibitor | PTGER2, PTGES2, PTGER1 | LTB4R 37/4885LTB4R2 24/4885PPARD 802/4885 |
| US-20170042858-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | GHSR, GHRHR, GIPR | LTB4R 2345/4885LTB4R2 2939/4885PPARD 361/4885 |
| US-20040105883-A1 | Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage | PTGS2, PTGES2, PTGER2 | LTB4R 78/4885LTB4R2 28/4885PPARD 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.